Agreements reached under this partnership
Business Alliance- 1
The companies will combine FunPep's antibody-inducing peptide technology with Crafton Biotechnology's proprietary mRNA technology, including PureCap®, to create new therapeutic mRNA vaccines.
- 2
For the designed mRNA vaccines, Crafton Biotechnology will be responsible for synthesis, while FunPep will handle efficacy evaluations and other activities.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
FunPep is expected to bear the costs related to the activities for which it is responsible under the joint research project. However, there is no change to the forecast for research and development expenses for the fiscal year ending December 2026.
| Item | Details |
|---|---|
| Name of alliance partner | Crafton Biotechnology Co., Ltd. |
| Alliance partner's business activities | Research, development, manufacture, sale and technology transfer of pharmaceuticals |
| Alliance partner's location | Chikusa-ku, Nagoya, Aichi Prefecture |
| Type of alliance | Business Alliance |
| Details of the alliance | The companies will combine FunPep's antibody-inducing peptide technology with Crafton Biotechnology's proprietary mRNA technology, including PureCap®, to create new therapeutic mRNA vaccines., For the designed mRNA vaccines, Crafton Biotechnology will be responsible for synthesis, while FunPep will handle efficacy evaluations and other activities. |
| Impact on Business Performance | FunPep is expected to bear the costs related to the activities for which it is responsible under the joint research project. However, there is no change to the forecast for research and development expenses for the fiscal year ending December 2026. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To combine the technologies of both companies and create new therapeutic mRNA vaccines.